NCT01282268已完成3 期
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome
Seaside Therapeutics, Inc.24 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2011年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 125
- 试验地点
- 24
- 主要终点
- Aberrant Behavior Checklist - FXS Social Avoidance Subscale
研究概览
简要总结
To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in adolescents and adults with fragile X syndrome (FXS)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 50 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Molecular documentation of the full FMR1 mutation
- •Current pharmacological treatment regimen has been stable for at least 4 weeks prior to Screening.
- •Subjects with a history of seizure disorder must currently be receiving treatment with antiepileptics and must have been seizure free for 6 months, or must be seizure free for 3 years if not currently receiving antiepileptics.
- •If the subject is already receiving stable non-pharmacologic educational, behavioral, and/or dietary interventions, participation in these programs must have been continuous during the 2 months prior to Screening
排除标准
- •Subjects with any condition, including alcohol and drug abuse, which might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being.
- •Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.
- •Subjects who have taken another investigational drug within the last 30 days.
- •Subjects who are not able to take oral medications.
研究组 & 干预措施
Arbaclofen
Active Comparator
干预措施: arbaclofen (Drug)
Placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Aberrant Behavior Checklist - FXS Social Avoidance Subscale
时间窗: At 8 weeks of treatment
次要结局
未报告次要终点
研究者
研究点 (24)
Loading locations...
相似试验
已完成
2 期
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum DisordersAutism Spectrum DisordersNCT01288716Seaside Therapeutics, Inc.150
已完成
2 期
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X SyndromeFragile X SyndromeNCT00788073Seaside Therapeutics, Inc.63
已完成
2 期
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back SpasmsBack PainNCT00817986XenoPort, Inc.161
撤回
3 期
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MSSpermMultiple SclerosisNCT02869425RVL Pharmaceuticals, Inc.
已完成
3 期
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)Major Depressive DisorderNCT00035282Merck Sharp & Dohme LLC450